期刊
MOVEMENT DISORDERS
卷 36, 期 6, 页码 1456-1460出版社
WILEY
DOI: 10.1002/mds.28616
关键词
Parkinson' s; GBA; haplotypes; intronic variants; genetics
资金
- Celgene
- GlaxoSmithKline (GSK)
- Michael J. Fox Foundation for Parkinson's Research
- National Institute of Neurological Disorders and Stroke
- Pfizer
- Sanofi
- Verily
- National Institute for Neurological Disorders and Stroke
- philanthropy
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke at the National Institutes of Health
- MRC [MR/M006646/1] Funding Source: UKRI
Through studying a large cohort, we found that GBA haplotypes do not affect age at diagnosis of PD.
Background GBA mutations are a common risk factor for Parkinson's disease (PD). A recent study has suggested that GBA haplotypes, identified by intronic variants, can affect age at diagnosis of PD. Objectives In this study, we assess this hypothesis using long reads across a large cohort and the publicly available Accelerating Medicines Partnership-Parkinson's Disease (AMP-PD) cohort. Methods We recruited a PD cohort through the Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease study (RAPSODI) and sequenced GBA using Oxford Nanopore technology. Genetic and clinical data on the full AMP-PD cohort were obtained from the online portal of the consortium. Results A total of 1417 participants were analyzed. There was no significant difference in age at PD diagnosis between the two main haplotypes of the GBA gene. Conclusions GBA haplotypes do not affect age at diagnosis of PD in the two independent cohorts studied. (c) 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据